Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV)

J Med Vasc. 2024 Sep;49(3-4):170-175. doi: 10.1016/j.jdmv.2024.08.001. Epub 2024 Aug 27.

Abstract

Obesity is an alarming worldwide public health issue and is defined as a body mass index (BMI) of 30kg/m2 or more. It is considered as a risk factor for first thrombotic event and is associated with a significant risk of recurrence. Consequently, obese patients are often treated by anticoagulant therapy but data from randomised control trial are scarce. We will review in this narrative review the state of the art of the prescription of anticoagulant for the prevention and treatment of venous thromboembolism (VTE) in obese patients.

Keywords: Anticoagulants; Obesity; Venous thromboembolism disease.

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Anticoagulants* / administration & dosage
  • Anticoagulants* / adverse effects
  • Anticoagulants* / therapeutic use
  • Body Mass Index
  • Consensus
  • Humans
  • Obesity* / complications
  • Recurrence
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / etiology
  • Venous Thromboembolism* / prevention & control

Substances

  • Anticoagulants